Clinical Trial Update: L-DEP as an Initial Treatment for EBV-HLH [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating L-DEP as initial therapy for EBV-associated Hemophagocytic Lymphohistiocytosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ebv-associated Hemophagocytic Lymphohistiocytosis
• Hemophagocytic Lymphohistiocytosis

Drugs mentioned

• L-DEP (L-DEP)

Snippet

Sponsor: Beijing Friendship Hospital | Conditions: Hemophagocytic Lymphohistiocytosis | Phase 3 | Status: UNKNOWN